 |
市場調查報告書
商品編碼
1741151
細菌疫苗市場按疫苗類型、患者年齡層、給藥途徑、銷售管道和地區分類Bacterial Vaccines Market, By Vaccine Type, By Patient Age Group, By Route of Administration, By Distribution Channel, By Geography |
||||||
價格
簡介目錄
細菌疫苗市場規模預計在 2025 年為 277.2 億美元，預計到 2032 年將達到 475.1 億美元，2025 年至 2032 年的年複合成長率為 8%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025年的市場規模 | 277.2億美元 |
| 效能數據 | 從2020年到2024年 | 預測期 | 2025年至2032年 |
| 預測期：2025-2032年年複合成長率： | 8.00% | 2032年價值預測 | 475.1億美元 |
細菌疫苗含有能夠活化免疫系統的弱化或去活化細菌。它是預防醫學中對抗結核病、霍亂、炭疽、流感、破傷風、腦膜炎、傷寒等感染疾病的重要方法。政府和非政府組織正在進行多項項目，以宣傳包括感染疾病在內的預防醫學的益處。
市場動態：
預計全球細菌疫苗市場在預測期內將顯著成長。這主要是因為世界各國政府正在採取重大舉措，確保全球人口能夠獲得預防致命感染疾病的藥物。此外，疫情期間疫苗接種需求的增加也推動了市場的發展。此外，新型感染疾病去氧核糖核酸(DNA) 疫苗的推出也推動了市場的發展。 COVID-19 疫情影響了各種 DNA 疫苗的研發，從而對細菌疫苗市場的成長產生了積極影響。抗生素抗藥性細菌性疾病發生率的上升再次推動了細菌疫苗市場的成長。這促使主要市場參與者專注於開發更有效的感染疾病並投資於研究活動。
然而，對細菌性疾病缺乏認知預計會阻礙細菌疫苗市場的成長。
例如，2023年9月28日，英國政府決定向伯明罕大學主辦的細菌疫苗網路（BactiVac）提供140萬美元的資助，以加速開發細菌疫苗，預防感染疾病爆發，這是全球抗抗抗生素抗藥性（AMR）行動的一部分。細菌疫苗在對抗AMR方面發揮關鍵作用，可以預防感染疾病的發生並減少抗生素的使用需求。
本研究的主要特點
- 本報告對全球細菌疫苗市場進行了詳細分析，並以 2024 年為基準年，提供了 2025 年至 2032 年預測期內的市場規模和年複合成長率(CAGR)。
- 它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
- 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
- 它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，介紹了全球細菌疫苗市場的主要企業概況。
- 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
- 全球細菌疫苗市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員將透過用於分析全球細菌疫苗市場的各種策略矩陣來做出決策。
目錄
第1章 調查目的與前提條件
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章市場動態、法規與趨勢分析
- 市場動態
- 促進要素
- 限制因素
- 機會
- 主要亮點
- 監管情景
- 近期動態
- 產品發布/核准
- PEST分析
- 波特分析
- 合併、收購和合作
4. 全球細菌疫苗市場-冠狀病毒（COVID-19）大流行的影響
- COVID-19流行病學
- 供需側分析
- 經濟影響
5. 2020 年至 2032 年全球細菌疫苗市場（依疫苗類型）
- 百日咳疫苗
- 破傷風疫苗
- 白喉疫苗
- 肺炎鏈球菌疫苗
- 腦膜炎雙球菌疫苗
- 傷寒疫苗
- 結核病（TB）疫苗
- 霍亂疫苗
- 志賀氏菌病疫苗
- 其他
6. 2020-2032 年全球細菌疫苗市場（依病患年齡層）
- 兒童疫苗（嬰兒、兒童）
- 青少年疫苗
- 成人疫苗
- 老年人疫苗
7. 2020 年至 2032 年按給藥途徑分類的全球細菌疫苗市場
- 肌肉注射
- 靜脈
- 皮下
- 其他
8. 2020 年至 2032 年全球細菌疫苗市場（依通路）
- 公共
- 私人的
9. 2020 年至 2032 年全球細菌疫苗市場（按地區）
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東地區
- 非洲
- 南非
- 北非
- 中部非洲
第10章 競爭格局
- Company Profie
- GSK plc
- Pfizer Inc.
- Merck & Co., Inc.
- Sanofi
- Johnson & Johnson Service, Inc.
- Serum Institute of India Pvt. Ltd.
- Bharat Biotech
- Biological E. Limited
- Astellas Pharma Inc.
- Seqirus（CSL Limited）
- AstraZeneca
- Novavax, Inc.
- Bavarian Nordic A/S
- Emergent BioSolutions Inc.
- Valneva SE
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim International GmbH
- Immunomic Therapeutics, Inc.
- Moderna, Inc.
- Clover Biopharmaceuticals
- Analysts'Views
第 11 章 章節
- 參考
- 調查方法
- 關於出版商
簡介目錄
Product Code: CMI5877
Bacterial Vaccines Market is estimated to be valued at USD 27.72 Bn in 2025 and is expected to reach USD 47.51 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 27.72 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.00% | 2032 Value Projection: | USD 47.51 Bn |
Bacterial vaccines contain mild or killed forms of bacteria that activate the immune system. This is a vital method for preventive medicine to fight infections like tuberculosis, cholera, anthrax, influenza, tetanus, meningitis, and typhoid. Several programs are carried out by governments and non-governmental organizations to spread awareness about the benefits of the preventive medicines including vaccines against infectious diseases.
Market Dynamics:
Global bacterial vaccines market is expected to grow at a substantial rate during the forecast period. This is mainly due to significant initiatives undertaken by governments across the globe to ensure that the preventive medicine for lethal infectious diseases is available for the population across the world. The market is also fueled by the increasing demand for vaccinations during pandemics. Moreover, the market is driven by the launch of new Deoxyribonucleic acid (DNA) vaccines against infectious diseases. The Covid-19 pandemic has influenced the development of a variety of DNA vaccines and hence positively impacted the growth of the bacterial vaccines market. The rising incidence of antibiotic-resistant bacterial diseases is again driving the growth of bacterial vaccines market. This is influencing the key market players to invest in research activities by focusing on developing more effective vaccines against infectious diseases.
However, lack of awareness regarding the bacterial disease is expected to hinder the market growth of the bacterial vaccines
For instance, on September 28, 2023, the U.K. government awarded the University of Birmingham-hosted Bacterial Vaccines Network (BactiVac) US$ 1.4 million in funding to accelerate the development of bacterial vaccines in a bid to prevent infections from occurring as part of the global fight against antimicrobial resistance (AMR). Bacterial vaccines play a critical role in the fight against AMR, both through preventing infections from developing and reducing the need to use antimicrobials.
Key features of the study:
- This report provides in-depth analysis of the global bacterial vaccines market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global bacterial vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include GSK plc., Pfizer Inc., Merck & Co., Inc., Sanofi, Johnson & Johnson Service, Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech Biological E. Limited, Astellas Pharma Inc., Seqirus (CSL Limited), AstraZeneca, Novavax, Inc., Bavarian Nordic A/S, Emergent BioSolutions Inc., Valneva SE, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Immunomic Therapeutics, Inc., Moderna, Inc., Clover Biopharmaceuticals
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global bacterial vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bacterial vaccines market
Global Bacterial Vaccines Market Detailed Segmentation:
- By Vaccine Type
- Pertussis (Whooping Cough) Vaccines
- Tetanus Vaccines
- Diphtheria Vaccines
- Pneumococcal Vaccines
- Meningococcal Vaccines
- Typhoid Vaccines
- Tuberculosis (TB) Vaccines
- Cholera Vaccines
- Shigellosis Vaccines
- Others
- By Patient Age Group
- Pediatric Vaccines (Infants, Children)
- Adolescent Vaccines
- Adult Vaccines
- Geriatric Vaccines
- By Route of Administration
- Intramuscular
- Intravenous
- Subcutaneous
- Others (Oral, Nasal among others)
- By Distribution Channel
- Public
- Private
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
- Company Profile
- GSK Plc
- Pfizer Inc.
- Merck & Co., Inc.
- Sanofi
- Johnson & Johnson Service, Inc.
- Serum Institute of India Pvt. Ltd.
- Bharat Biotech
- Biological E. Limited
- Astellas Pharma Inc.
- Seqirus (CSL Limited)
- AstraZeneca
- Novavax, Inc.
- Bavarian Nordic A/S
- Emergent BioSolutions Inc.
- Valneva SE
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim International GmbH
- Immunomic Therapeutics, Inc.
- Moderna, Inc.
- Clover Biopharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Vaccine Type
- Market Snippet, By Patient Age Group
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraints
- Opportunities
- Key Highlights
- Regulatory Scenario
- Recent Trends
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Mergers, Acquisitions, and Collaborations
4. Global Bacterial Vaccines Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Bacterial Vaccines Market, By Vaccine Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pertussis (Whooping Cough) Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Tetanus Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Diphtheria Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Pneumococcal Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Meningococcal Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Typhoid Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Tuberculosis (TB) Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Cholera Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Shigellosis Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
6. Global Bacterial Vaccines Market, By Patient Age Group, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric Vaccines (Infants, Children)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Adolescent Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Adult Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Geriatric Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
7. Global Bacterial Vaccines Market, By Route of Administration, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
8. Global Bacterial Vaccines Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
9. Global Bacterial Vaccines Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 -2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Company Profie
- GSK plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Johnson & Johnson Service, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Serum Institute of India Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bharat Biotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biological E. Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Seqirus (CSL Limited)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novavax, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bavarian Nordic A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Emergent BioSolutions Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Valneva SE
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Immunomic Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Moderna, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Clover Biopharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analysts' Views
11. Section
- References
- Research Methodology
- About us
